Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TBK1 | Q9UHD2 | 6/20 | 0.40 |
| ▸ | HRH3 | Q9Y5N1 | 6/20 | 0.40 |
| ▸ | SCN7A | Q01118 | 3/20 | 0.40 |
| ▸ | HRH2 | P25021 | 2/20 | 0.40 |
| ▸ | HRH1 | P35367 | 2/20 | 0.40 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.39 |
| ▸ | SCN2A | Q99250 | 1/20 | 0.39 |
| ▸ | SCN8A | Q9UQD0 | 1/20 | 0.39 |
| ▸ | ESR1 | P03372 | 4/20 | 0.38 |
| ▸ | ESR2 | Q92731 | 2/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4091084 | 0.98 | TBK1 (0.41) | TBK1HRH3SCN7AHRH2HRH1 | |
| SCHEMBL4083874 | 0.98 | SCN7A (0.42) | TBK1HRH3SCN7AHRH2HRH1 | |
| SCHEMBL5381490 | 0.89 | BACE1 (0.43) | TBK1HRH3ESR1ESR2 | |
| SCHEMBL4079707 | 0.89 | HRH3 (0.49) | HRH3HRH2HRH1ESR1 | |
| SCHEMBL4095624 | 0.89 | HRH3 (0.45) | HRH3HRH2HRH1ESR1 | |
| SCHEMBL4095621 | 0.89 | HRH3 (0.45) | HRH3HRH2HRH1ESR1 | |
| SCHEMBL4082983 | 0.88 | SLC6A2 (0.38) | — | |
| SCHEMBL4083905 | 0.88 | HRH3 (0.44) | HRH3HRH2HRH1ESR1 | |
| SCHEMBL4084194 | 0.87 | EGLN2 (0.42) | HRH3SCN7AHRH2HRH1SCN5A | |
| SCHEMBL4079425 | 0.87 | HRH3 (0.47) | HRH3HRH2HRH1ESR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2065383-A1 | Indazole compounds and methods of use thereof as protein kinase inhibitors | Signal Pharmaceuticals, Inc. (US) | 2009-06-03 | — | — | EP | disclosed |
| US-20090099178-A1 | INDAZOLE COMPOUNDS AND METHODS OF USE THEREOF | BHAGWAT SHRIPAD S | 2009-04-16 | — | — | US | disclosed |
| US-20060004043-A1 | Indazole compounds and methods of use thereof | BHAGWAT SHRIPAD S | 2006-01-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090099178-A1 | INDAZOLE COMPOUNDS AND METHODS OF USE THEREOF | WNT3, WNT3A, WNK3 | TBK1 126/4885HRH3 2504/4885SCN7A 2498/4885 |
| US-20060004043-A1 | Indazole compounds and methods of use thereof | WNT3, WNT3A, WNK3 | TBK1 148/4885HRH3 2769/4885SCN7A 2639/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.